

SmartPA Criteria Proposal

Drug/Drug Class:	Diabetic Supply Quantity Limit Fiscal Edit
First Implementation Date:	March 1, 2019
Proposed Date:	December 17, 2020
Prepared for:	MO HealthNet
Prepared by:	MO HealthNet/Conduent
Criteria Status:	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: To control expenditures by setting quantity limits on diabetic supplies

Why Issue Selected: Government research has indicated that blood glucose test strips have a limited benefit for many patients who do not take insulin to manage their diabetes. Also, as of April 2020, MO HealthNet now covers continuous glucose monitors (CGMs) for qualifying participants, decreasing the reliance on frequent blood glucose testing for many participants. Urine ketone test strips may be used to determine if a participant is producing ketones due to a ketogenic diet or diabetic ketoacidosis. MO HealthNet desires to provide diabetic supplies to all qualifying participants, and as such, it is fiscally advantageous for MO HealthNet to establish limits to the number of urine ketone test strips it will reimburse for patients, as well as to continue limits for blood glucose test strips.

Program-Specific Information:	Date Range FFS 10-01-2019 to 9-30-2020			
	Drug	Claims	Spend	Avg Spend per Claim
	BLOOD GLUCOSE TEST STRIPS	76,900	\$9,994,151.25	\$130.11
	URINE KETONE TEST STRIPS	1,403	\$41,563.60	\$27.26

Type of Criteria: Increased risk of ADE Preferred Drug List
 Appropriate Indications Fiscal Edit

Data Sources: Only Administrative Databases Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Blood Glucose Test Strips **and Urine Ketone Test Strips**
- Age range: All appropriate MO HealthNet participants

Approval Criteria

- **For urine ketone test strips: max 100 test strips every 75 days**

SmartPA Fiscal Proposal Form

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

- For blood glucose test strips:
 - Documented history of a continuous glucose monitor (CGM) in the past 120 days: max 100 test strips every 75 days OR
 - No documented history of a continuous glucose monitor (CGM) in the past 120 days:
 - Participants ≤ 18 years of age: max 900 test strips every 75 days
 - Participant > 18 years of age:
 - Currently pregnant: max 350 test strips every 75 days
 - Insulin Dependent: max 400 test strips every 75 days
 - Non-Insulin Dependent: max 100 test strips every 75 days

Denial Criteria

- Therapy will be denied if all approval criteria are not met

Required Documentation

Laboratory Results:
MedWatch Form:

Progress Notes:
Other:

X

Disposition of Edit

Denial: Exception code "0234" (Dose Optimization)
Rule Type: PD

Default Approval Period

1 year

References

- Centers for Medicare & Medicaid Services. Medicare Coverage of Blood Glucose Monitors and Testing Supplies. <https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/downloads/SE1008.pdf>. Accessed November 3, 2020.
- American Diabetes Association. 7. Diabetes technology: Standards of Medical Care in Diabetes - 2019. Diabetes Care 2019;42 (Suppl. 1):S71–S80

SmartPA Fiscal Proposal Form

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.